Clinical Trial Update: A Study of Combination Treatment With an HCV Polymerase Inhibitor (RO5024048) and an HCV Protease Inhibitor (RO5190591/Danoprevir) in Genotype 1 Chronic Hepatitis C Patients [Phase 1]

View source ↗

Summary

A Phase 1 study evaluated a combination of RO5024048 and RO5190591/Danoprevir in genotype 1 chronic hepatitis C patients; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• RO5024048
• RO5190591/Danoprevir (Danoprevir)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Hepatitis C, Chronic | Phase 1 | Status: COMPLETED